Raleigh, NCNCT07067463Now EnrollingIRB Ready

Multiple Sclerosis (MS) Primary Progressive Clinical Trial in Raleigh, NC

Access cutting-edge multiple sclerosis (ms) primary progressive treatment through this clinical trial at a research site in Raleigh. Study-provided care at no cost to qualified participants.

Sponsored by Zenas BioPharma (USA), LLC

Quick Self-Assessment

See if you qualify for this Raleigh location

Preparing your pre-screening questions…

Expert Care in Raleigh

Access multiple sclerosis (ms) primary progressive specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple sclerosis (ms) primary progressive treatment provided free

Apply for This Raleigh Location

Check if you qualify for this multiple sclerosis (ms) primary progressive clinical trial in Raleigh, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Raleigh

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Raleigh site if eligible
  4. 4Begin participation

About This Multiple Sclerosis (MS) Primary Progressive Study in Raleigh

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Sponsor: Zenas BioPharma (USA), LLC

Who Can Participate

Inclusion Criteria

18 to 60 years of age, inclusive
Diagnosed with Primary Progressive MS (PPMS) according to 2017 McDonald criteria
Participant must have documented evidence of disability progression observed during the 24 months before screening.
Expanded disability status scale (EDSS) score between 3.0 to 6.5 points, inclusive, at Screening.

Exclusion Criteria

Diagnosed with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
Immunologic disorder other than MS or any other conditions requiring oral, intravenous (IV), intramuscular, or intra-articular corticosteroid therapy.
History or current diagnosis of other neurological disorders that may mimic MS
History of any other significant active medical condition
History of suicidal behavior within 6 months prior to Screening
Any prior history of malignancy if no recurrence within 5 years
Patients on anticoagulation, or antiplatelet therapy will be excluded
Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducerswithin 14 days
Clinically significant laboratory abnormalities at Screening.
Any allergy, contraindication, or inability to tolerate orelabrutinib or any of the excipients in the study intervention
Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Raleigh?

Yes, this clinical trial (NCT07067463) has an active research site in Raleigh, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Sclerosis (MS) Primary Progressive Treatment Options in Raleigh, NC

If you're searching for multiple sclerosis (ms) primary progressive treatment options in Raleigh, NC, this clinical trial (NCT07067463) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Raleigh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple sclerosis (ms) primary progressive specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple sclerosis (ms) primary progressive clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Raleigh, NC

See all multiple sclerosis clinical trials recruiting in Raleigh — not just this study.

Browse Multiple Sclerosis Trials in Raleigh →

Browse More Trials by Condition

Multiple Sclerosis TrialsAll Conditions →

Ready to Join in Raleigh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Raleigh, NC